Search Results

By Emily Castellanos, MD, MPH, and Neal J. Meropol, MD  / February 10, 2020

How Real-World Data Can Help Contextualize New Treatments in Older Patients

Consider a patient who is referred for neoadjuvant therapy for stage IIIA, HER2-positive breast cancer. She is otherwise healthy, with no significant medical history, an Eastern Cooperative Oncology Group performance status of 0, unremarkable baseline labs, and a left-ventricular ejection fraction...